Clinical Trial

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

Study acronym: CHIMERA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label, multi-site Phase II trial of pembrolizumab in combination with pemetrexed and cisplatin or carboplatin as neo-adjuvant therapy followed by surgery and adjuvant pembrolizumab in patients affected by resectable stage I-IIIa chemonaïve epithelioid/biphasic pleural mesothelioma.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-11-30; most recent amendment 2026-01-12.
Status change: Recruiting → Active, Not Recruiting 2026-01-12
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06155279
Lead Sponsor Istituto Oncologico Veneto IRCCS
Collaborators: MSD Italia S.r.l.
Conditions Pleural Mesothelioma
Enrollment 41 participants
Start Date 2024-11-06
Primary Completion 2025-12-22 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-13